Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06527365 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of VDPHL01 in Males and Females With AGA
A Phase 2 study of Androgenetic Alopecia and AGA, sponsored by Veradermics.
- Active
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 4
- Study locations
NCT06527365 is a Phase 2 study of Androgenetic Alopecia and AGA that is active but no longer recruiting, run by Veradermics. The registered enrollment target is 70 participants, below the 160-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (56% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06527365, a Phase 2 study of Androgenetic Alopecia and AGA, is active but no longer recruiting, sponsored by Veradermics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness. This multiple center, open-label, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). Male subjects that meet the study eligibility criteria will be administered VDPHL01 once daily for 12 months. Female subjects that meet the study eligibility criteria will be administered VDPHL01 either once or twice daily for 12 months.
Conditions Studied
Interventions
- DRUG VDPHL01
Study Locations (4)
California
- 01 - San Diego
Indiana
- 04 - New Albany
New Jersey
- 03 - Hackensack
Utah
- 02 - South Jordan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-07-08 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06527365
The ClinicalTrials.gov registry entry for NCT06527365 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (56% lower). The listed sponsor is Veradermics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which VDPHL01 is the first listed.
NCT06527365 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Indiana, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06527365 about?
NCT06527365 is a clinical study titled "Safety and Efficacy of VDPHL01 in Males and Females With AGA". This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets...
What is the current status of trial NCT06527365?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2024-07-08. Estimated completion is 2026-08.
What conditions does trial NCT06527365 study?
This clinical trial studies the following conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness.
What interventions are being tested in trial NCT06527365?
The interventions under investigation include: VDPHL01 (DRUG).
Who is sponsoring clinical trial NCT06527365?
This trial is sponsored by Veradermics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06527365 being conducted?
This trial has 4 study locations across California, Indiana, New Jersey, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
COMPLETED · Phase 2
-
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
COMPLETED · Phase 2
-
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
COMPLETED · Phase 2
-
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.